Kura Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kura Oncology, Inc. on May 7, 2019. The filing serves to announce the Company's financial results for the first quarter ended March 31, 2019, and provides a corporate update. The detailed financial data is contained in the press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this Form 8-K.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative financial analysis.
Guidance, Outlook, and Risks
The Company issued a corporate update alongside the financial results. The filing explicitly states that the information contained in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor will it be incorporated by reference into any registration statement unless specifically identified.
Key Facts for Investor Verification
- Verify the specific Q1 2019 financial figures (revenue, net loss, cash position) in the attached press release (Exhibit 99.1).
- Review the corporate update for any changes in clinical trial progress or strategic direction.
- Note that the financial data in this filing is not legally "filed" under Section 18 of the Exchange Act.
- Confirm the Company's status as an emerging growth company, as indicated by the checkmark in the filing.